{
    "code": "02023859",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02023859",
    "time": "2021-03-26 04:23:57",
    "許可證字號": "衛署藥輸字第023859號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "112\/10\/23",
    "發證日期": "92\/10\/23",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202385907",
    "中文品名": "維思通&#174;肌肉注射用懸液劑37.5毫克",
    "英文品名": "RISPERDAL CONSTA&#174; 37.5MG SUSPENSION FOR I.M. INJECTION",
    "適應症": "治療急性及慢性思覺失調症之精神病及其他有明顯活性症狀(如幻覺、妄想、思考障礙、敵意、多疑)和\/或負性症狀(如情感遲滯、情緒和社交退縮、缺乏言談)的精神異常狀況。RISPERDAL CONSTA亦可減輕伴隨思覺失調症產生之情感症(如抑鬱、愧疚感、焦慮)。\r\nRisperdal Consta可合併鋰鹽及Valproate以預防快速循環型雙極性疾患(Rapid cycling bipolar disorder)之復發。\r\nRisperdal Consta可單獨使用作為非快速循環型之第一型雙極性疾患病患的維持治療，以預防狂躁或混合型復發。",
    "劑型": "240乾粉注射劑",
    "包裝": "裝溶劑，100支以下盒裝 37.5毫克小瓶 預充填注射針筒裝 Access Device每盒附2支注射用安全針頭(GLUTEAL INJECTION NEEDLE及DELTOID INJECTION NEEDLE)及1個VIAL ADAPTER",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "RISPERIDONE",
    "限制項目": "02輸　入",
    "申請商名稱": "1507401100  嬌生股份有限公司",
    "申請商地址": "台北市中山區民生東路三段2號10樓及11樓",
    "主製造廠": [
        {
            "製造廠名稱": "FUS0352000  ALKERMES INCORPORATED (MICROSPHERES)",
            "製造廠廠址": "ALKERMES-265 OLINGER CIRCLE WILMINGTON, OHIO 45177 U.S.A.",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "粉劑製造廠"
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "6132061151  裕利股份有限公司",
            "製造廠廠址": "桃園市大園區和平里1鄰開和路91號",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "二級包裝廠(委託貼標及置入仿單)"
        },
        {
            "製造廠名稱": "6605071926  久裕企業股份有限公司",
            "製造廠廠址": "桃園市桃園區大林里興邦路43巷2之1號4樓，3樓B區，1樓A區",
            "製造廠公司地址": "",
            "製造廠國別": "",
            "製程": "委託包裝廠(貼標)"
        },
        {
            "製造廠名稱": "FBE0009000  JANSSEN PHARMACEUTICA N.V.",
            "製造廠廠址": "TURNHOUTSEWEG 30 B-2340 BEERSE",
            "製造廠公司地址": "",
            "製造廠國別": "BELGIUM",
            "製程": "許可證持有者"
        },
        {
            "製造廠名稱": "FCH0015000  CILAG AG.",
            "製造廠廠址": "HOCHSTRASSE 201 CH-8200 SCHAFFHAUSEN SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "溶液劑製造廠"
        }
    ],
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "2816100600",
            "成分名稱": "RISPERIDONE",
            "含量描述": "",
            "含量": "37.5000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Risperdal Consta 37.5mg New Kit_CSP-108-03-26(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023859&Seq=002&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "[打樣版] Risperdal Consta_CCDS 07Apr2020_v2101_20201214-110-01-13.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023859&Seq=073&Type=9"
        },
        {
            "title": "Risperdal consta 37.5mg_Box v03-108-07-30(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023859&Seq=005&Type=8"
        },
        {
            "title": "Risperdal consta 37.5mg_Box v02-108-02-19(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023859&Seq=004&Type=8"
        }
    ]
}